A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
BACKGROUND Although greater than 40% of breast cancers occur in patients aged ≥65 years, these individuals are frequently undertreated. Taxane-based adjuvant chemotherapy is considered the treatment of choice but to the authors' knowledge has only limited evidence in elderly patients. METHODS P...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 25, 2015
|
| In: |
Cancer
Year: 2015, Volume: 121, Issue: 20, Pages: 3639-3648 |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.29506 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.29506 Verlag, lizenzpflichtig, Volltext: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.29506 
|
| Author Notes: | Gunter von Minckwitz, MD; Bettina Conrad, MD; Toralf Reimer, MD; Thomas Decker, MD; Holger Eidtmann, MD; Wolfgang Eiermann, MD; John Hackmann, MD; Volker Möbus, MD; Frederik Marmé, MD; Jochem Potenberg, MD; Elmar Stickeler, MD; Eike Simon, MD; Christoph Thomssen, MD; Jens Huober, MD; Carsten Denkert, MD;Joachim Alfer, MD; Christian Jackisch, MD; Valentina Nekljudova, PhD; Nicole Burchardi, PhD; and Sibylle Loibl, MD; for the German Breast Group Investigators |